Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(SSNT)Float 1 M /PE 2 / RALLYYYYYYYYYYYYYYYYYYYYYYYYY Market cap only $13 Million
(EYEG) Float 2M-about TO EXPLODE --MC $17 M--Float 2 M -Fiing for US approval for BIG Eye Drug expected this Quarter / Share price $3.65 ...Stock could explode back to $10++ again
"In the second half of 2020, we anticipate several important milestones, including the completion of testing required to use cost-effective OBG packaging in the PE pivotal study, the filing of the IDE for our PE pivotal study, and the submission of the de novo application for commercialization of our OBG eye drop in patients who have undergone PRK surgery."
Presentation
https://file///C:/Users/berns/AppData/Local/Temp/EyeGate-Corporate-Presentation-Sept-2020-1.pdf
EYEG: Raising Target on positive pipeline progress....September 28, 2020
https://finance.yahoo.com/news/eyeg-raising-target-positive-pipeline-150500023.html
Based on the Company’s positive progress, we are raising our valuation from $12.00 to $15.00 based on a 10-year DCF with terminal market shares of 15-20% in the US for both its PRK and PE products, 20% royalties, 10% discount rate, 20% terminal EBIT margin, 25% tax rate and $6 million in net cash.
(EYEG) Float 2M-about TO EXPLODE --MC $17 M--Float 2 M -Fiing for US approval for BIG Eye Drug expected this Quarter / Share price $3.65 ...Stock could explode back to $10++ again
"In the second half of 2020, we anticipate several important milestones, including the completion of testing required to use cost-effective OBG packaging in the PE pivotal study, the filing of the IDE for our PE pivotal study, and the submission of the de novo application for commercialization of our OBG eye drop in patients who have undergone PRK surgery."
Presentation
https://file///C:/Users/berns/AppData/Local/Temp/EyeGate-Corporate-Presentation-Sept-2020-1.pdf
EYEG: Raising Target on positive pipeline progress....September 28, 2020
https://finance.yahoo.com/news/eyeg-raising-target-positive-pipeline-150500023.html
Based on the Company’s positive progress, we are raising our valuation from $12.00 to $15.00 based on a 10-year DCF with terminal market shares of 15-20% in the US for both its PRK and PE products, 20% royalties, 10% discount rate, 20% terminal EBIT margin, 25% tax rate and $6 million in net cash.
(EYEG)Float 2M-about TO EXPLODE --MC $17 M--Float 2 M -Fiing for US approval for BIG Eye Drug expected this Quarter / Share price $3.65 ...Stock could explode back to $10++ again
"In the second half of 2020, we anticipate several important milestones, including the completion of testing required to use cost-effective OBG packaging in the PE pivotal study, the filing of the IDE for our PE pivotal study, and the submission of the de novo application for commercialization of our OBG eye drop in patients who have undergone PRK surgery."
Presentation
https://file///C:/Users/berns/AppData/Local/Temp/EyeGate-Corporate-Presentation-Sept-2020-1.pdf
EYEG: Raising Target on positive pipeline progress....September 28, 2020
https://finance.yahoo.com/news/eyeg-raising-target-positive-pipeline-150500023.html
Based on the Company’s positive progress, we are raising our valuation from $12.00 to $15.00 based on a 10-year DCF with terminal market shares of 15-20% in the US for both its PRK and PE products, 20% royalties, 10% discount rate, 20% terminal EBIT margin, 25% tax rate and $6 million in net cash.
VSQTF =MC $35 M/Covid 19 Test approved in USA and in Europe in LAST days / UNKNOWN stock =Potential 10++ Bagger guys
Victory Square gets FDA OK for 15 min COVID-19 test...2020-10-13
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2974156
Victory Square Health receives EU nod for Safetest...2020-09-14
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2962366
Victory Square unit gets order for 2M Safetest tests
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2967882
VSQTF =MC $35 M/Covid 19 Test approved in USA and in Europe in LAST days / UNKNOWN stock =Potential 10++ Bagger guys
Victory Square gets FDA OK for 15 min COVID-19 test...2020-10-13
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2974156
Victory Square Health receives EU nod for Safetest...2020-09-14
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2962366
Victory Square unit gets order for 2M Safetest tests
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2967882
Why Is Victory Square Technologies Such A Unique Tech Opportunity?
VSQTF =MC $35 M/Covid 19 Test approved in USA and in Europe in LAST days / UNKNOWN stock =Potential 10++ Bagger guys
Victory Square gets FDA OK for 15 min COVID-19 test...2020-10-13
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2974156
Victory Square Health receives EU nod for Safetest...2020-09-14
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2962366
VSQTF =MC $39 M-Covid 19 Test approved in USA (today) and last month in Europe / UNKNOWN stock = A Potential 10++ BAGGER GEM
Victory Square gets FDA OK for 15 min COVID-19 test...2020-10-13
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2974156
Victory Square Health receives EU nod for Safetest...2020-09-14
https://www.stockwatch.com/News/Item/?bid=Z-C:VST-2962366
MARPS =RALLYYYYYYYYYYYYYYYYYYYYY
and still valued at laughable $4 million
MARPS about to EXPLODE guys only 2 million outstanding shares and has a terrible low valuation of laughable $4 million
MARPS =RALLYYYYYY only 2 million outstanding shares and has a terrible low valuation of laughable $4 million
MARPS about to EXPLODE guys only 2 million outstanding shares and has a terrible low valuation of laughable $4 million
(MARPS) MC $3 M-Shares Out 2 M-Profitable Oil Company / price $1.75...Undiscovered low float monster which could hit $10 in NO time ....LIFETIME OPP guys
(MARPS) MC $3 M-Shares Out 2 M-Profitable Oil Company...Undiscovered low float monster which could hit $10 in NO time ....LIFETIME OPP guys
MARPS =MC $3 M/ Shares Out 2 M / PROFITABLE Oil Company ...this could explode like a nuclear bomb once it gets discovered
MARPS =MC $3 M / O/S 2 M / Profitable Company...Undiscovered low float monster which could hit $10 in NO time
LIFE=Trading under Cash / Covid 19 Drug with IMMINENT results
LIFE = MCap $35 Mil trading UNDER Cash / Covid 19 Phase 2 results IMMINENT, positive results could lead to fast FDA approval via EUA approval=UNKNOWN Gem with 10++ BAGGER Potential
Oppenheimer: These 3 Penny Stocks Have Triple-Digit Upside Potential
https://finance.yahoo.com/news/oppenheimer-3-penny-stocks-triple-193042532.html
The Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications is progressing right on track, with a topline readout set to come by YE20.
Part of what makes the therapy stand out is its unique mechanism of action, which makes it well suited for use in treating severe respiratory complications, in Singh’s opinion. Importantly, based on the therapy’s preclinical model in ARDS, the analyst argues LIFE could potentially establish PoC efficacy data in COVID-19 prior to PS.
This prompted Singh to comment, “We believe ATYR1923's ‘blue sky scenario’ in COVID-19 patients looks promising, given the lack of novel targeted therapies for severe respiratory complications by SARS-CoV-2 and other triggers... We see a likelihood that, under such a rigorous trial design, positive data could potentially get ATYR1923 an emergency use authorization without having to expand into a full Phase 3.”
If that wasn’t enough, Singh thinks LIFE’s NRP2 science has “significant opportunities beyond the current pipeline. This could be expanded into additional inflammatory/fibrotic lung diseases and cancers in 2021.”
Expounding on this, Singh said, “Expected by YE20 is an IND monoclonal antibody aTyr will declare from its Neuropilin-2 (NRP2) antibody program. Multiple NRP2 antibodies demonstrated anti-tumor effects; one of them (aNRP2-10) blocked VEGF-C binding to NRP2, exhibiting increased sensitivity to chemotherapy in preclinical models of triple-negative breast cancer (TNBC).”
Based on all of the above, Singh rates LIFE an Outperform (i.e. Buy) along with an $12 price target.
LIFE = MCap $35 Mil trading UNDER Cash / Covid 19 Phase 2 results IMMINENT, positive results could lead to fast FDA approval via EUA approval=UNKNOWN Gem with 10++ BAGGER Potential
Oppenheimer: These 3 Penny Stocks Have Triple-Digit Upside Potential
https://finance.yahoo.com/news/oppenheimer-3-penny-stocks-triple-193042532.html
The Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications is progressing right on track, with a topline readout set to come by YE20.
Part of what makes the therapy stand out is its unique mechanism of action, which makes it well suited for use in treating severe respiratory complications, in Singh’s opinion. Importantly, based on the therapy’s preclinical model in ARDS, the analyst argues LIFE could potentially establish PoC efficacy data in COVID-19 prior to PS.
This prompted Singh to comment, “We believe ATYR1923's ‘blue sky scenario’ in COVID-19 patients looks promising, given the lack of novel targeted therapies for severe respiratory complications by SARS-CoV-2 and other triggers... We see a likelihood that, under such a rigorous trial design, positive data could potentially get ATYR1923 an emergency use authorization without having to expand into a full Phase 3.”
If that wasn’t enough, Singh thinks LIFE’s NRP2 science has “significant opportunities beyond the current pipeline. This could be expanded into additional inflammatory/fibrotic lung diseases and cancers in 2021.”
Expounding on this, Singh said, “Expected by YE20 is an IND monoclonal antibody aTyr will declare from its Neuropilin-2 (NRP2) antibody program. Multiple NRP2 antibodies demonstrated anti-tumor effects; one of them (aNRP2-10) blocked VEGF-C binding to NRP2, exhibiting increased sensitivity to chemotherapy in preclinical models of triple-negative breast cancer (TNBC).”
Based on all of the above, Singh rates LIFE an Outperform (i.e. Buy) along with an $12 price target.
LIFE = MC $35 Mil trading UNDER Cash / Covid 19 Phase 2 results IMMINENT, positive results could lead to fast FDA approval via EUA approval=UNKNOWN Gem with 10++ Bagger Potential
LIFE about to EXPLODE like AGEX
Covid 19 Phase 2 results imminent / Market Cap $34 million trading under cash
LIFE =trading UNDER Cash/ Covid 19 Phase 2 results anyday now =Potential 10 Bagger UPSIDE GEM....Undiscovered stock
Market Cap $34 million / Cash $42 million / Shares Out 10 Million
"The Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications is progressing right on track, with a topline readout set to come by YE20.
Part of what makes the therapy stand out is its unique mechanism of action, which makes it well suited for use in treating severe respiratory complications, in Singh’s opinion. Importantly, based on the therapy’s preclinical model in ARDS, the analyst argues LIFE could potentially establish PoC efficacy data in COVID-19 prior to PS.
This prompted Singh to comment, “We believe ATYR1923's ‘blue sky scenario’ in COVID-19 patients looks promising, given the lack of novel targeted therapies for severe respiratory complications by SARS-CoV-2 and other triggers... We see a likelihood that, under such a rigorous trial design, positive data could potentially get ATYR1923 an emergency use authorization without having to expand into a full Phase 3.”
If that wasn’t enough, Singh thinks LIFE’s NRP2 science has “significant opportunities beyond the current pipeline. This could be expanded into additional inflammatory/fibrotic lung diseases and cancers in 2021.”
Expounding on this, Singh said, “Expected by YE20 is an IND monoclonal antibody aTyr will declare from its Neuropilin-2 (NRP2) antibody program. Multiple NRP2 antibodies demonstrated anti-tumor effects; one of them (aNRP2-10) blocked VEGF-C binding to NRP2, exhibiting increased sensitivity to chemotherapy in preclinical models of triple-negative breast cancer (TNBC).”
Based on all of the above, Singh rates LIFE an Outperform (i.e. Buy) along with an $12 price target. "
https://finance.yahoo.com/news/oppenheimer-3-penny-stocks-triple-193042532.html
LIFE =trading UNDER Cash/ Covid 19 Phase 2 results anyday now =Potential 10 Bagger UPSIDE GEM....Undiscovered stock
Market Cap $34 million / Cash $42 million / Shares Out 10 Million
"The Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications is progressing right on track, with a topline readout set to come by YE20.
Part of what makes the therapy stand out is its unique mechanism of action, which makes it well suited for use in treating severe respiratory complications, in Singh’s opinion. Importantly, based on the therapy’s preclinical model in ARDS, the analyst argues LIFE could potentially establish PoC efficacy data in COVID-19 prior to PS.
This prompted Singh to comment, “We believe ATYR1923's ‘blue sky scenario’ in COVID-19 patients looks promising, given the lack of novel targeted therapies for severe respiratory complications by SARS-CoV-2 and other triggers... We see a likelihood that, under such a rigorous trial design, positive data could potentially get ATYR1923 an emergency use authorization without having to expand into a full Phase 3.”
If that wasn’t enough, Singh thinks LIFE’s NRP2 science has “significant opportunities beyond the current pipeline. This could be expanded into additional inflammatory/fibrotic lung diseases and cancers in 2021.”
Expounding on this, Singh said, “Expected by YE20 is an IND monoclonal antibody aTyr will declare from its Neuropilin-2 (NRP2) antibody program. Multiple NRP2 antibodies demonstrated anti-tumor effects; one of them (aNRP2-10) blocked VEGF-C binding to NRP2, exhibiting increased sensitivity to chemotherapy in preclinical models of triple-negative breast cancer (TNBC).”
Based on all of the above, Singh rates LIFE an Outperform (i.e. Buy) along with an $12 price target. "
https://finance.yahoo.com/news/oppenheimer-3-penny-stocks-triple-193042532.html
Great buying opportunity here close at ATL ,,,dirt cheap stock at $72 million valuation which has 2 phase 3 drugs with first readout expected next quarter . A potential 10 bagger and more here ..GL
Presentation October
https://investors.entasistx.com/static-files/0bf75506-2d54-4b14-896a-6a3d5ed53472
Major Shareholders
Innoviva Inc ...18.7M
Armistice ...3.5M
AstraZeneca PLC ...2.2M
Clarus Ventures, LLC ...1.3M
Pivotal ...1.2M
Sofinnova ...1.2M
Novo Holdings A/S ...1.2M
TPG Capital, L.P....1.0M
Eventide Asset ...879.5K
Frazier ...350.0K
CTIC = RALLYYYYYYYYYYYYYY
CTIC =Covid Phase 3 Data within 4 months if positive this stock could explode to $20 and more curently trading at $2.50
WAVE.V =MCap C$ 9 Million / 5x Cancer Drugs approved in Europe ,market launch expected next Quarter / 2 additional BIG Cancer Drugs awaiting approval in US and Europe expected to be approved in Q4 2020 / Another 6 Cancer Drugs acquired early this month / Its also a covid 19 gem too = UNDISCOVERED stock with MASSIVE Upside Potential could be a 20 Bagger or more ....
Waverley Pharma (WAVE.V) canadian stock
Market Cap C$ 9 million
Price 0.15
Waverley Pharma Announces Signing of Term Sheet to Acquire Exclusive Rights to Market Six Generic Oncology Products in the United States
https://finance.yahoo.com/news/electric-royalties-closes-acquisition-bissett-114500612.html
The brands represented by these six generic products, referred to by the Company as WAV-103, WAV-104, WAV-105, WAV-106, WAV-107 and WAV-108, had combined sales of more than $3 billion USD in 2019.
Pipeline
https://www.waverleypharma.com/generic-product-pipeline.html
WAV-101 is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications. Currently there is no marketed generic version for this product in the United States, and the brand generates yearly revenue of over $1 billion USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
WAV-102 is an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. Currently there is no marketed generic for this product and the brand generates yearly revenue of over $800 million USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
CTIC a Covid 19 Phase 3 gem with results expected next quarter , this is a MONSTER Play and very cheap stock
CTIC up 110% after Hours could be a HOT play for tomorrow
CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia
https://finance.yahoo.com/news/cti-biopharma-submit-drug-application-200500351.html